Literature DB >> 31445411

Cytotoxic CD4+ T-cells during HIV infection: Targets or weapons?

Alexandra Sanchez-Martinez1, Federico Perdomo-Celis1, Liliana Acevedo-Saenz2, Maria T Rugeles1, Paula A Velilla3.   

Abstract

Classically, CD4+ T-cells have been referred as cytokine-producing cells and important players in immune responses by providing soluble factors that potentiate several effector immune functions. However, it is now evident that CD4+ T-cells can also elaborate cytotoxic responses, inducing apoptosis of target cells. Cytotoxic CD4+ T cells (CD4+ CTLs), exhibit cytolytic functions that resemble those of CD8+ T-cells; in fact, there is evidence suggesting that they may have a role in the control of viral infections. In this article, we discuss the role of CD4+ CTLs during HIV infection, where CD4+ CTLs have been associated with viral control and slow disease progression. In addition, we address the implication of CD4+ CTLs in the context of antiretroviral therapy and the partial reconstitution of CD8+ T-cells effector function.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD107a; CD4; Cytotoxic; Granzyme B; HIV; Perforin

Mesh:

Substances:

Year:  2019        PMID: 31445411     DOI: 10.1016/j.jcv.2019.08.004

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  DEC-205 receptor-mediated long-circling nanoliposome as an antigen and Eucommia ulmoides polysaccharide delivery system enhances the immune response via facilitating dendritic cells maturation.

Authors:  Haibo Feng; Xiaonong Yang; Jing Fan; Linzi Zhang; Qianqian Liu; Dongkun Chai
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

2.  T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19.

Authors:  Olatz Zenarruzabeitia; Gabirel Astarloa-Pando; Iñigo Terrén; Ane Orrantia; Raquel Pérez-Garay; Iratxe Seijas-Betolaza; Javier Nieto-Arana; Natale Imaz-Ayo; Silvia Pérez-Fernández; Eunate Arana-Arri; Francisco Borrego
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

3.  Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.

Authors:  Amélie Cachot; Mariia Bilous; Yen-Cheng Liu; Xiaokang Li; Margaux Saillard; Mara Cenerenti; Georg Alexander Rockinger; Tania Wyss; Philippe Guillaume; Julien Schmidt; Raphaël Genolet; Giuseppe Ercolano; Maria Pia Protti; Walter Reith; Kalliopi Ioannidou; Laurence de Leval; Joseph A Trapani; George Coukos; Alexandre Harari; Daniel E Speiser; Alexander Mathis; David Gfeller; Hatice Altug; Pedro Romero; Camilla Jandus
Journal:  Sci Adv       Date:  2021-02-26       Impact factor: 14.136

Review 4.  Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy.

Authors:  Myriam Ben Khelil; Yann Godet; Syrine Abdeljaoued; Christophe Borg; Olivier Adotévi; Romain Loyon
Journal:  Cancers (Basel)       Date:  2022-01-05       Impact factor: 6.639

5.  Diminished Peripheral CD29hi Cytotoxic CD4+ T Cells Are Associated With Deleterious Effects During SIV Infection.

Authors:  Omalla A Olwenyi; Samuel D Johnson; Kabita Pandey; Michellie Thurman; Arpan Acharya; Shilpa J Buch; Howard S Fox; Anthony T Podany; Courtney V Fletcher; Siddappa N Byrareddy
Journal:  Front Immunol       Date:  2021-10-13       Impact factor: 7.561

6.  Enhanced SARS-CoV-2-Specific CD4+ T Cell Activation and Multifunctionality in Late Convalescent COVID-19 Individuals.

Authors:  Nathella Pavan Kumar; Kadar Moideen; Arul Nancy; Nandhini Selvaraj; Rachel Mariam Renji; Saravanan Munisankar; Jeromie Wesley Vivian Thangaraj; Santhosh Kumar Muthusamy; C P Girish Kumar; Tarun Bhatnagar; Manickam Ponnaiah; Sabarinathan Ramasamy; Saravanakumar Velusamy; Manoj Vasant Murhekar; Subash Babu
Journal:  Viruses       Date:  2022-03-02       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.